KORU Medical Systems Partners for Advancements in Nephrology Care

KORU Medical Systems Partners for Advancements in Nephrology Care

KORU Medical Systems (NASDAQ: KRMD), a prominent leader in the medical technology space, is excited to announce its collaboration with a global pharmaceutical manufacturer for a groundbreaking Phase III clinical trial. This clinical trial focuses on an expanded indication for an existing drug designed to treat a rare renal disorder, addressing the needs of a patient population of approximately 30,000 individuals. With around 300,000 infusions expected annually, this partnership signifies a pivotal moment in enhancing patient care.

Innovative Solutions in Drug Delivery

This development underscores KORU Medical's ongoing commitment to innovation and collaboration within the healthcare sector. The Phase III trial aims to thoroughly evaluate the safety, effectiveness, and overall performance of the drug therapy in managing complications related to kidney transplants. Such advancements are crucial as they highlight the importance of improving the quality of life for patients who face rare health challenges.

Growth in Subcutaneous Infusion Market

Linda Tharby, President and CEO of KORU Medical, expressed enthusiasm for the expanding large volume subcutaneous market, noting, "We continue to see growth in the overall large volume subcutaneous market with multiple new drugs entering clinical trials and several others receiving regulatory approval. With over 2 million infusions administered on the KORU Freedom Infusion System every year, KORU continues to be a leading collaboration partner for large volume subcutaneous drug therapies in both home and infusion clinic settings.”

Empowering Patients with Rare Renal Disorders

Tharby further emphasized the significance of the upcoming trial: "Assuming successful completion and results from this Phase III clinical trial, this drug’s expanded indication will give us access to a new patient base and enable the delivery of a therapy to improve the lives of those with rare renal disorder.” This forward-thinking approach ensures that patients receive the necessary treatments to enhance their health and well-being.

About KORU Medical Systems

KORU Medical Systems is dedicated to the development, manufacturing, and commercialization of innovative solutions in large volume subcutaneous infusion. Their products, such as the FREEDOM Syringe Infusion System—including the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers—have revolutionized patient care for self-administration or delivery in healthcare environments. The Freedom System has been a staple since its FDA clearance in 1994, continually evolving to meet the needs of patients. Furthermore, KORU Medical actively supports biopharmaceutical companies through its Novel Therapies division, providing tailored solutions for clinical trials and drug development processes.

Frequently Asked Questions

What is the main purpose of the Phase III trial conducted by KORU Medical?

The Phase III trial aims to evaluate the safety and efficacy of an expanded indication for an existing drug treatment for patients with renal disorders.

How many patients could potentially benefit from the new drug indication?

The trial is expected to help approximately 30,000 patients who are dealing with rare renal disorders.

What role does KORU Medical play in the subcutaneous infusion market?

KORU Medical is a leader in developing innovative subcutaneous infusion solutions, with significant annual infusion administration using their systems.

What are some products developed by KORU Medical Systems?

KORU Medical manufactures several infusion solutions, including the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers.

What does KORU Medical's Novel Therapies division do?

The Novel Therapies division supports biopharmaceutical companies in clinical trials and can customize infusion systems for various drug categories.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.